PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0700
0.00 (0.00%)
At close: Nov 13, 2026
PURE Bioscience Income Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
| 2.32 | 2.2 | 1.96 | 1.88 | 1.85 | |
Revenue Growth | 5.27% | 12.17% | 4.58% | 1.29% | -52.81% |
Cost of Revenue | 0.99 | 0.9 | 0.81 | 0.91 | 0.85 |
Gross Profit | 1.33 | 1.3 | 1.15 | 0.97 | 1 |
Selling, General & Admin | 3.08 | 3.26 | 3.98 | 4.3 | 4.05 |
Research & Development | 0.33 | 0.32 | 0.3 | 0.3 | 0.32 |
Operating Expenses | 3.41 | 3.58 | 4.28 | 4.6 | 4.37 |
Operating Income | -2.08 | -2.27 | -3.13 | -3.63 | -3.37 |
Interest Expense | -0.41 | -0.3 | -0.16 | -0.01 | -0.01 |
Other Non Operating Income (Expenses) | 0.01 | 0.17 | -0 | -0 | - |
EBT Excluding Unusual Items | -2.48 | -2.4 | -3.29 | -3.65 | -3.38 |
Asset Writedown | - | - | -0.06 | -0.32 | -0.35 |
Other Unusual Items | - | - | - | - | 0.24 |
Pretax Income | -2.48 | -2.4 | -3.35 | -3.96 | -3.49 |
Net Income | -2.48 | -2.4 | -3.35 | -3.96 | -3.49 |
Net Income to Common | -2.48 | -2.4 | -3.35 | -3.96 | -3.49 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 116 | 112 | 112 | 111 | 89 |
Shares Outstanding (Diluted) | 116 | 112 | 112 | 111 | 89 |
Shares Change | 4.11% | 0.01% | 0.41% | 25.41% | 1.91% |
EPS (Basic) | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
EPS (Diluted) | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Free Cash Flow | -1.74 | -2.02 | -2.53 | -3.31 | -2.5 |
Free Cash Flow Per Share | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 |
Gross Margin | 57.20% | 59.17% | 58.69% | 51.73% | 53.97% |
Operating Margin | -89.86% | -103.18% | -159.50% | -193.29% | -181.87% |
Profit Margin | -107.12% | -108.95% | -170.66% | -211.03% | -188.40% |
Free Cash Flow Margin | -74.98% | -91.51% | -128.94% | -176.40% | -134.86% |
EBITDA | -2.08 | -2.27 | -2.98 | -3.51 | -3.16 |
EBITDA Margin | -89.73% | -103.09% | -151.96% | -187.05% | -170.37% |
D&A For EBITDA | 0 | 0 | 0.15 | 0.12 | 0.21 |
EBIT | -2.08 | -2.27 | -3.13 | -3.63 | -3.37 |
EBIT Margin | -89.86% | -103.18% | -159.50% | -193.29% | -181.87% |
Revenue as Reported | 2.32 | 2.2 | 1.96 | 1.88 | 1.85 |